BlueSphere Bio, Inc.

PITTSBURGH, PA · Founded 2017 · Biotech · Private

TCR-engineered T cell therapies for cancer and rare diseases

Claim this profile

Follows are private to you and power your alerts

Updated · bluespherebio.com

Sector
Biotech
Headquarters
PITTSBURGH, PA
Founded
2017
Latest Form D
$46M, Dec 2020
Total capital
$56M
Grants
—
No SBIR or STTR on record
Sector median 1 award
Raised
$56M
2 Form D · Dec 2020
70 months since last filing
Contracts
—
No federal contracts on record
Patents
22
0 granted · 22 pending
11× sector median 2 patents

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history, newest first
DateEventSourceAmount
Private capital raisedForm D · SEC$45,637,472
Private capital raisedForm D · SEC$10,000,016
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3384MouSensor, Inc.——
3385AGEX THERAPEUTICS INC—$19M
3386Ultragenyx Pharmaceutical Inc.—$109M
3387BlueSphere Bio, Inc.—$56M
3388Life Biosciences LLC—$54M
3389PhaseBio Pharmaceuticals Inc—$64M
3390OPUS GENETICS INC.—$47M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 7 related persons
  • David ApelianDirector · Executive Officer
  • Jeanne CunicelliDirector
  • Tal HeppenstallDirector
  • Alan KormanDirector
  • Robert LinDirector
  • Mark ShlomchikDirector · Executive Officer
  • Warren ShlomchikExecutive Officer

Patents

USPTO · 0 granted of 22
  • T CELL RECEPTORS (TCRs) TARGETING MINOR HISTOCOMPATIBILITY ANTIGEN HA-1application
  • T Cell Receptors Targeting Minor Histocompatibility Antigen ACC-1application
  • T Cell Receptors Targeting An NPM1 Neoantigenapplication
  • T Cell Receptors Targeting A NPM1 Neoantigenapplication
  • T Cell Receptors Targeting Minor Histocompatibility Antigen LRH-1application
  • T Cell Receptors Targeting Minor Histocompatibility Antigen ACC-1application
  • Methods For Identifying T Cell Receptors (tcrs) That Bind Antigensapplication
  • T Cell Receptors Targeting Minor Histocompatibility Antigen HA-2application
  • T Cell Receptors Targeting A NPM1 Neoantigenapplication
  • Allogeneic T Cells For Treatment Of Hematological Malignanciesapplication
  • Allogeneic T Cells For Treatment Of Hematological Malignancisapplication
  • Methods For Identifying T Cell Receptors (TCRs) that Bind Antigensapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.